Palliative splenectomy in myelofibrosis with myeloid metaplasia

Ruben Mesa, A. Tefferi

Research output: Contribution to journalReview article

13 Citations (Scopus)

Abstract

Myelofibrosis with myeloid metaplasia (MMM) is a chronic myeloproliferative disorder in which the accumulation and growth of circulating myeloid progenitors in the spleen lead to pathologic enlargement of the organ with resulting mechanical discomfort, hypercatabolic symptoms, anemia, thrombocytopenia, and portal hypertension. Medical therapy and splenic irradiation may be of benefit in certain patients, yet many may still require splenectomy to palliate their symptoms. Although there is no clear survival advantage to splenectomy in MMM, the procedure can result in substantial palliation of symptoms. However, the surgical procedure is associated with an approximately 9% mortality rate, and the postsplenectomy occurrence of extreme thrombocytosis, hepatomegaly, and leukemic transformation is of major concern. The management of splenomegaly and the role of splenectomy in MMM are discussed in this review.

Original languageEnglish (US)
Pages (from-to)901-911
Number of pages11
JournalLeukemia and Lymphoma
Volume42
Issue number5
DOIs
StatePublished - Jan 1 2001
Externally publishedYes

Fingerprint

Primary Myelofibrosis
Splenectomy
Thrombocytosis
Myeloproliferative Disorders
Hepatomegaly
Splenomegaly
Portal Hypertension
Thrombocytopenia
Anemia
Spleen
Survival
Mortality
Growth
Therapeutics

Keywords

  • Myelofibrosis
  • Myeloid metaplasia
  • Splenectomy

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Palliative splenectomy in myelofibrosis with myeloid metaplasia. / Mesa, Ruben; Tefferi, A.

In: Leukemia and Lymphoma, Vol. 42, No. 5, 01.01.2001, p. 901-911.

Research output: Contribution to journalReview article

@article{0a5ae6f910f345d1b0a13669bd53dc69,
title = "Palliative splenectomy in myelofibrosis with myeloid metaplasia",
abstract = "Myelofibrosis with myeloid metaplasia (MMM) is a chronic myeloproliferative disorder in which the accumulation and growth of circulating myeloid progenitors in the spleen lead to pathologic enlargement of the organ with resulting mechanical discomfort, hypercatabolic symptoms, anemia, thrombocytopenia, and portal hypertension. Medical therapy and splenic irradiation may be of benefit in certain patients, yet many may still require splenectomy to palliate their symptoms. Although there is no clear survival advantage to splenectomy in MMM, the procedure can result in substantial palliation of symptoms. However, the surgical procedure is associated with an approximately 9{\%} mortality rate, and the postsplenectomy occurrence of extreme thrombocytosis, hepatomegaly, and leukemic transformation is of major concern. The management of splenomegaly and the role of splenectomy in MMM are discussed in this review.",
keywords = "Myelofibrosis, Myeloid metaplasia, Splenectomy",
author = "Ruben Mesa and A. Tefferi",
year = "2001",
month = "1",
day = "1",
doi = "10.3109/10428190109097709",
language = "English (US)",
volume = "42",
pages = "901--911",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - Palliative splenectomy in myelofibrosis with myeloid metaplasia

AU - Mesa, Ruben

AU - Tefferi, A.

PY - 2001/1/1

Y1 - 2001/1/1

N2 - Myelofibrosis with myeloid metaplasia (MMM) is a chronic myeloproliferative disorder in which the accumulation and growth of circulating myeloid progenitors in the spleen lead to pathologic enlargement of the organ with resulting mechanical discomfort, hypercatabolic symptoms, anemia, thrombocytopenia, and portal hypertension. Medical therapy and splenic irradiation may be of benefit in certain patients, yet many may still require splenectomy to palliate their symptoms. Although there is no clear survival advantage to splenectomy in MMM, the procedure can result in substantial palliation of symptoms. However, the surgical procedure is associated with an approximately 9% mortality rate, and the postsplenectomy occurrence of extreme thrombocytosis, hepatomegaly, and leukemic transformation is of major concern. The management of splenomegaly and the role of splenectomy in MMM are discussed in this review.

AB - Myelofibrosis with myeloid metaplasia (MMM) is a chronic myeloproliferative disorder in which the accumulation and growth of circulating myeloid progenitors in the spleen lead to pathologic enlargement of the organ with resulting mechanical discomfort, hypercatabolic symptoms, anemia, thrombocytopenia, and portal hypertension. Medical therapy and splenic irradiation may be of benefit in certain patients, yet many may still require splenectomy to palliate their symptoms. Although there is no clear survival advantage to splenectomy in MMM, the procedure can result in substantial palliation of symptoms. However, the surgical procedure is associated with an approximately 9% mortality rate, and the postsplenectomy occurrence of extreme thrombocytosis, hepatomegaly, and leukemic transformation is of major concern. The management of splenomegaly and the role of splenectomy in MMM are discussed in this review.

KW - Myelofibrosis

KW - Myeloid metaplasia

KW - Splenectomy

UR - http://www.scopus.com/inward/record.url?scp=0034851886&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034851886&partnerID=8YFLogxK

U2 - 10.3109/10428190109097709

DO - 10.3109/10428190109097709

M3 - Review article

VL - 42

SP - 901

EP - 911

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 5

ER -